Product Information
ADVAIR HFA 115-21 MCG INHALER is a brand product labeled by GlaxoSmithKline LLC, priced at $25.3928 per GM under NDC 00173071620. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 8, 2006.
Strength
115; 21 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173071620
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
New Drug (NDA)
FDA Application
NDA021254FDA Approved
6/8/2006
On Market Since
9/29/2008
Pharmacological Classes
Price Statistics
The NADAC for ADVAIR HFA 115-21 MCG INHALER has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 18.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $25.3928 per GM |
|---|---|
| All-time high | $32.4703 (Aug 10, 2022) |
| All-time low | $21.4800 (Nov 28, 2013) |
| 52-week high | $25.4390 |
| 52-week low | $25.3928 |
| Median price | $28.9093 |
| Average price | $28.5368 |
| Largest weekly change | -21.4% (Dec 27, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 26% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone propionate and salmeterol xinafoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADVAIR HFA 115-21 MCG INHALER?
The current National Average Drug Acquisition Cost (NADAC) for ADVAIR HFA 115-21 MCG INHALER, manufactured by GlaxoSmithKline LLC, is $25.3928 per GM (NDC 00173071620), effective Sep 30, 2026.
How has the price of ADVAIR HFA 115-21 MCG INHALER changed over time?
Over the history we have for it, the NADAC for ADVAIR HFA 115-21 MCG INHALER has risen 18.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ADVAIR HFA 115-21 MCG INHALER?
Since Nov 28, 2013, the NADAC for ADVAIR HFA 115-21 MCG INHALER has ranged from a low of $21.4800 (Nov 28, 2013) to a high of $32.4703 (Aug 10, 2022), with a median of $28.9093 per GM.
Are there cheaper alternatives to ADVAIR HFA 115-21 MCG INHALER?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ADVAIR HFA 115-21 MCG INHALER, is $18.7312 per GM — about 26% below ADVAIR HFA 115-21 MCG INHALER.
Who manufactures ADVAIR HFA 115-21 MCG INHALER?
ADVAIR HFA 115-21 MCG INHALER (NDC 00173071620) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.